Century Therapeutics Inc. is a cell therapy company. It involved in developing induced pluripotent stem cell -derived cell therapies in immuno-oncology. Century Therapeutics Inc. is based in PHILADELPHIA.
| Revenue (Most Recent Fiscal Year) | $6.59M |
| Net Income (Most Recent Fiscal Year) | $-126.57M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 0.46 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.22 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -17.54% |
| Net Margin (Trailing 12 Months) | -19.10% |
| Return on Equity (Trailing 12 Months) | -10.71% |
| Return on Assets (Trailing 12 Months) | -5.96% |
| Current Ratio (Most Recent Fiscal Quarter) | 11.70 |
| Quick Ratio (Most Recent Fiscal Quarter) | 11.70 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.90 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.89 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.61 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.29 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 86.16M |
| Free Float | 80.30M |
| Market Capitalization | $53.10M |
| Average Volume (Last 20 Days) | 0.72M |
| Beta (Past 60 Months) | 1.77 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 6.80% |
| Percentage Held By Institutions (Latest 13F Reports) | 50.20% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |